<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778049</url>
  </required_header>
  <id_info>
    <org_study_id>1275.10</org_study_id>
    <secondary_id>2012-002271-34</secondary_id>
    <nct_id>NCT01778049</nct_id>
  </id_info>
  <brief_title>Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes</brief_title>
  <official_title>A Phase III, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Linagliptin 5 mg Compared to Placebo, Administered as Oral Fixed Dose Combination With Empagliflozin 10 mg or 25 mg for 24 Weeks, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks of Treatment With Empagliflozin 10 mg or 25 mg on Metformin Background Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate the efficacy, safety and tolerability of
      linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM
      patients on empagliflozin 10 mg or 25 mg and maximum tolerated dose of metformin. The primary
      objective of efficacy evaluation is planned after 24 weeks of treatment. The study is
      designed to show superiority of the combination of empagliflozin and linagliptin over
      empagliflozin alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline of HbA1c After 24 Weeks of Treatment.</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change from baseline in Glycated haemoglobin (HbA1c) [%] after 24 weeks of treatment with double-blind trial medication, i.e. HbA1c change from baseline at Week 24. The term &quot;baseline&quot; was not used to refer to measurements prior to the administration of open-label medication. Such measurements were referred to as &quot;pre-treatment&quot;. Analyses of change from pre-treatment used the last value before first administration of open-label medication as point of reference.
Observed Case (OC): This method analyse only available data that were observed while patients were on treatment, i.e., excluding the missing data. All values measured after rescue medication taken were set to missing. Full Analysis Set (FAS): Includes all patients in the Treated set who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the double-blind part of the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Change from baseline FPG (mmol/L) after 24 weeks of treatment with double-blind trial medication, i.e. FPG change from baseline at Week 24.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">708</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Empagliflozin 10 mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin open label treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo add on 10 mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin/Linagliptin 25/5 mg Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin / Linagliptin 25/5 mg Dose FDC active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin/Linagliptin 10/5 mg Dose.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin/Linagliptin 10/5 mg Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin / Linagliptin 10/5 mg Dose FDC active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin 25 mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin open label treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin/Linagliptin 25/5 mg Dose.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo add on 25 mg dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>Empagliflozin active</description>
    <arm_group_label>Placebo add on 25 mg dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 Placebo</intervention_name>
    <description>Empagliflozin placebo</description>
    <arm_group_label>Empagliflozin/Linagliptin 10/5 mg Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 / BI 1356</intervention_name>
    <description>Empagliflozin / Linagliptin 25/5 mg Dose FDC active</description>
    <arm_group_label>Empagliflozin/Linagliptin 25/5 mg Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>Empagliflozin active</description>
    <arm_group_label>Empagliflozin 10 mg dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 / BI 1356</intervention_name>
    <description>Empagliflozin / Linagliptin 10/5 mg Dose FDC active</description>
    <arm_group_label>Empagliflozin/Linagliptin 10/5 mg Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 / BI 1356 Placebo</intervention_name>
    <description>Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC</description>
    <arm_group_label>Placebo add on 10 mg dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>Empagliflozin active</description>
    <arm_group_label>Placebo add on 10 mg dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>Empagliflozin active</description>
    <arm_group_label>Empagliflozin 25 mg dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>Empagliflozin active</description>
    <arm_group_label>Empagliflozin/Linagliptin 25/5 mg Dose.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 / BI 1356 Placebo</intervention_name>
    <description>Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo</description>
    <arm_group_label>Empagliflozin/Linagliptin 25/5 mg Dose.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 Placebo</intervention_name>
    <description>Empagliflozin placebo</description>
    <arm_group_label>Empagliflozin/Linagliptin 25/5 mg Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 / BI 1356 Placebo</intervention_name>
    <description>Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo</description>
    <arm_group_label>Empagliflozin/Linagliptin 10/5 mg Dose.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>Empagliflozin active</description>
    <arm_group_label>Empagliflozin/Linagliptin 10/5 mg Dose.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773 / BI 1356 Placebo</intervention_name>
    <description>Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo</description>
    <arm_group_label>Placebo add on 25 mg dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Signed and dated ICF (Informed Consent Form)

          2. Male or female on diet and exercise regime and on stable background metformin &gt; or
             equal to 1500 mg or maximun dose according to local label

          3. HBA1c (Glicoslated Hemoglobin) &gt; or equal to 8% and &lt; or equal to 10.5 % at Visit 1

          4. HbA1c &gt; or equal to 7 and &lt; or equal to 10.5 at Visit 4

          5. Age &gt; or equal to 18 years

          6. BMI (Body Mass Index) &lt; or equal to 45

        Exclusion criteria:

          1. Uncontrolled hyperglycemia during open label period and placebo add on &quot;run-in&quot; period

          2. Use of any other antidiabetic

          3. Renal function below 60 ml/min/1.73 m2

          4. Antiobesity drugs or aggresive diets

          5. Gastorintestinal surgeries

          6. Current systemic steroids or uncontrolled endocrine disorders other than Diabetes Type
             2

          7. Acute coronary syndrome and stroke within 3 months of informed consent

          8. Known allergies to DPP-IV (Dypeptidil Peptidase IV) or SGLT-2 (Sodium Glucose
             Transporter 2) inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1275.10.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Conyers</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elkton</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.01025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.54005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.54012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.54002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.54007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.54013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.54006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.54008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.54011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.54003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Godoy Cruz, Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.54009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.54004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salta</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.54001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Isidro</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.54010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zarate</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.61008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cardiff</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.61002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Ringwood</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heidelberg Heights</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.61009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mirrabooka</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.02004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.02001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.02003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chilliwack</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.02009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.02012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.02006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.02008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.02005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.02013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.02002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strathroy</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.02007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.02011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Drummondville</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.02010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.34014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ávila</city>
        <country>El Salvador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Asslar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elsterwerda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hatten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiel Kronshagen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pirna</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Ingbert/Oberwürzbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Unterschneidheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.49015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Latina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olbia (OT)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orbassano (TO)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pistoia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sesto San Giovanni (MI)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.39011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.35104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cantanhede</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.35112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.35103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sandim</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.35105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tornada</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.35108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valadares</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.35101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Canet de Mar</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.34008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Centelles</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.34009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.34012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Roca del Vallès</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.34010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.34011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mataró</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.34013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pineda de Mar</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.38007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnipropetrovs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1275.10.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zhytomyr</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>El Salvador</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2013</study_first_submitted>
  <study_first_submitted_qc>January 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <results_first_submitted>March 4, 2016</results_first_submitted>
  <results_first_submitted_qc>March 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2016</results_first_posted>
  <last_update_submitted>March 4, 2016</last_update_submitted>
  <last_update_submitted_qc>March 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects randomised to 16 week(wk) open-label (OL) treatment with either empagliflozin (empa) 25 or empa 10 treatment, thereafter subjects entered to 1 wk open label placebo (Plc) add-on period in order to complete further eligibility evaluations before being randomised into 1 of the 24 wk double-blind treatment groups.</recruitment_details>
      <pre_assignment_details>This was a randomised, double-blind, multi-national, parallel group trial. In this trial the treatment effects of linagliptin (lina) 5 compared with Plc were analysed as add-on to either empa 25 or empa 10. All trial treatments were administered in addition to metformin background treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Empa 10 mg OL</title>
          <description>Subjects were orally administered once daily empa 10 mg film-coated tablet for 16 wk during OL treatment period, thereafter patients received once daily fixed dose combination (FDC) placebo tablet matching to FDC empa 10 mg/lina 5 mg in addition to empa 10 mg for 1 week during open label placebo add-on treatment period.</description>
        </group>
        <group group_id="P2">
          <title>Empa 25 mg OL</title>
          <description>Subjects were orally administered once daily empa 25 mg film-coated tablet for 16 week during OL treatment period, thereafter patients received once daily FDC Plc tablet matching to FDC empa 25 mg/lina 5 mg in addition to empa 25 mg for 1 wk during open label placebo add-on treatment period.</description>
        </group>
        <group group_id="P3">
          <title>Lina5 (E10)</title>
          <description>Subjects were orally administered FDC empa 10 mg/lina 5 mg and placebo matching to empa 10 mg for 24 wk during the double-blind treatment period.</description>
        </group>
        <group group_id="P4">
          <title>Plc (E10)</title>
          <description>Subjects were orally administered empa 10 mg and matching placebo to FDC empa 10 mg/lina 5 mg for 24 wk during the double-blind treatment period.</description>
        </group>
        <group group_id="P5">
          <title>Lina5 (E25)</title>
          <description>Subjects were orally administered FDC empa 25 mg/lina 5 mg and placebo matching to empa 25 mg for 24 wk during the double-blind treatment period.</description>
        </group>
        <group group_id="P6">
          <title>Plc (E25)</title>
          <description>Subjects were orally administered empa 25 mg and matching placebo to FDC empa 25 mg/lina 5 mg for 24 wk during the double-blind treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open Label Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="354"/>
                <participants group_id="P2" count="355"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
                <participants group_id="P2" count="226"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="129"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double Blind Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="126"/>
                <participants group_id="P4" count="130"/>
                <participants group_id="P5" count="114"/>
                <participants group_id="P6" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="111"/>
                <participants group_id="P4" count="118"/>
                <participants group_id="P5" count="102"/>
                <participants group_id="P6" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The open-label treated set (OLTS) was used for the open label treatment period. This analysis set consisted of all patients who received at least 1 dose of open-label treatment during the trial.</population>
      <group_list>
        <group group_id="B1">
          <title>Empa 10 mg OL</title>
          <description>Subjects were orally administered once daily empa 10 mg film-coated tablet for 16 wk during OL treatment period, thereafter patients received once daily fixed dose combination (FDC) placebo tablet matching to FDC empa 10 mg/lina 5 mg in addition to empa 10 mg for 1 week during open label placebo add-on treatment period.</description>
        </group>
        <group group_id="B2">
          <title>Empa 25 mg OL</title>
          <description>Subjects were orally administered once daily empa 25 mg film-coated tablet for 16 week during OL treatment period, thereafter patients received once daily FDC Plc tablet matching to FDC empa 25 mg/lina 5 mg in addition to empa 25 mg for 1 wk during open label placebo add-on treatment period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="352"/>
            <count group_id="B2" value="354"/>
            <count group_id="B3" value="706"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" spread="9.6"/>
                    <measurement group_id="B2" value="56.7" spread="9.9"/>
                    <measurement group_id="B3" value="56.8" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline of HbA1c After 24 Weeks of Treatment.</title>
        <description>Change from baseline in Glycated haemoglobin (HbA1c) [%] after 24 weeks of treatment with double-blind trial medication, i.e. HbA1c change from baseline at Week 24. The term “baseline” was not used to refer to measurements prior to the administration of open-label medication. Such measurements were referred to as “pre-treatment&quot;. Analyses of change from pre-treatment used the last value before first administration of open-label medication as point of reference.
Observed Case (OC): This method analyse only available data that were observed while patients were on treatment, i.e., excluding the missing data. All values measured after rescue medication taken were set to missing. Full Analysis Set (FAS): Includes all patients in the Treated set who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the double-blind part of the trial.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>FAS (OC)</population>
        <group_list>
          <group group_id="O1">
            <title>Lina5 (E10)</title>
            <description>Subjects were orally administered FDC empa 10 mg/lina 5 mg and placebo matching to empa 10 mg for 24 wk during the double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Plc (E10)</title>
            <description>Subjects were orally administered empa 10 mg and matching placebo to FDC empa 10 mg/lina 5 mg for 24 wk during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Lina5 (E25)</title>
            <description>Subjects were orally administered FDC empa 25 mg/lina 5 mg and placebo matching to empa 25 mg for 24 wk during the double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Plc (E25)</title>
            <description>Subjects were orally administered empa 25 mg and matching placebo to FDC empa 25 mg/lina 5 mg for 24 wk during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of HbA1c After 24 Weeks of Treatment.</title>
          <description>Change from baseline in Glycated haemoglobin (HbA1c) [%] after 24 weeks of treatment with double-blind trial medication, i.e. HbA1c change from baseline at Week 24. The term “baseline” was not used to refer to measurements prior to the administration of open-label medication. Such measurements were referred to as “pre-treatment&quot;. Analyses of change from pre-treatment used the last value before first administration of open-label medication as point of reference.
Observed Case (OC): This method analyse only available data that were observed while patients were on treatment, i.e., excluding the missing data. All values measured after rescue medication taken were set to missing. Full Analysis Set (FAS): Includes all patients in the Treated set who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the double-blind part of the trial.</description>
          <population>FAS (OC)</population>
          <units>Percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.07"/>
                    <measurement group_id="O2" value="-0.21" spread="0.07"/>
                    <measurement group_id="O3" value="-0.58" spread="0.07"/>
                    <measurement group_id="O4" value="-0.10" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of lina5 (E10) vs. Plc (E10): change in HbA1c using a restricted maximum likelihood (REML)- based mixed model repeated measures (MMRM) approach. The model includes baseline HbA1c as linear covariates &amp; baseline estimated glomerula filtration rate (eGFR), geographical region, treatment, visit, visit by treatment interaction as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <method>Mixed Model Repeated Measure (MMRM)</method>
            <method_desc>The unstructured covariance structure has been used to fit the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
            <estimate_desc>Mean Difference (Final Values) is actually the adjusted mean difference calculated as lina5 (E10) minus Plc (E10) value.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of lina5 (E25) vs. Plc (E25): change in HbA1c using a restricted maximum likelihood (REML)- based mixed model repeated measures (MMRM) approach. The model includes baseline HbA1c as linear covariates &amp; baseline eGFR, geographical region, treatment, visit, visit by treatment interaction as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>MMRM</method>
            <method_desc>The unstructured covariance structure has been used to fit the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
            <estimate_desc>Mean Difference (Final Values) is actually the adjusted mean difference value calculated as lina5 (E25) minus Plc (E25).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.</title>
        <description>Change from baseline FPG (mmol/L) after 24 weeks of treatment with double-blind trial medication, i.e. FPG change from baseline at Week 24.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>FAS (OC)</population>
        <group_list>
          <group group_id="O1">
            <title>Lina5 (E10)</title>
            <description>Subjects were orally administered FDC empa 10 mg/lina 5 mg and placebo matching to empa 10 mg for 24 wk during the double-blind treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Plc (E10)</title>
            <description>Subjects were orally administered empa 10 mg and matching placebo to FDC empa 10 mg/lina 5 mg for 24 wk during the double-blind treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Lina5 (E25)</title>
            <description>Subjects were orally administered FDC empa 25 mg/lina 5 mg and placebo matching to empa 25 mg for 24 wk during the double-blind treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Plc (E25)</title>
            <description>Subjects were orally administered empa 25 mg and matching placebo to FDC empa 25 mg/lina 5 mg for 24 wk during the double-blind treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose (FPG) Change From Baseline at 24 Weeks.</title>
          <description>Change from baseline FPG (mmol/L) after 24 weeks of treatment with double-blind trial medication, i.e. FPG change from baseline at Week 24.</description>
          <population>FAS (OC)</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.18"/>
                    <measurement group_id="O2" value="0.21" spread="0.18"/>
                    <measurement group_id="O3" value="-0.68" spread="0.15"/>
                    <measurement group_id="O4" value="-0.24" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of lina5 (E10) vs. Plc (E10): change in FPG using a restricted maximum likelihood (REML)- based mixed model repeated measures (MMRM) approach. The model includes baseline HbA1c &amp; baseline eGFR as linear covariates, geographical region, treatment, visit, visit by treatment interaction as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0103</p_value>
            <method>MMRM</method>
            <method_desc>The unstructured covariance structure has been used to fit the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.15</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
            <estimate_desc>Mean Difference (Final Values) is actually the adjusted mean difference value calculated as lina5 (E10) minus Plc (E10).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of lina5 (E25) vs. Plc (E25): change in FPG using a restricted maximum likelihood (REML)- based mixed model repeated measures (MMRM) approach. The model includes baseline HbA1c &amp; baseline eGFR as linear covariates, geographical region, treatment, visit, visit by treatment interaction as fixed effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0452</p_value>
            <method>MMRM</method>
            <method_desc>The unstructured covariance structure has been used to fit the mixed model.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
            <estimate_desc>Mean Difference (Final Values) is actually the adjusted mean difference value calculated as lina5 (E25) minus Plc (E25).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 7 days after the last drug administration, up to 212 days (OL treatment period) and 205 days (double blind treatment period).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Empa 10 mg OL</title>
          <description>Subjects were orally administered once daily empa 10 mg film-coated tablet for 16 wk during OL treatment period, thereafter patients received once daily fixed dose combination (FDC) placebo tablet matching to FDC empa 10 mg/lina 5 mg in addition to empa 10 mg for 1 week during open label placebo add-on treatment period.</description>
        </group>
        <group group_id="E2">
          <title>Empa 25 mg OL</title>
          <description>Subjects were orally administered once daily empa 25 mg film-coated tablet for 16 week during OL treatment period, thereafter patients received once daily FDC Plc tablet matching to FDC empa 25 mg/lina 5 mg in addition to empa 25 mg for 1 wk during open label placebo add-on treatment period.</description>
        </group>
        <group group_id="E3">
          <title>Lina5 (E10)</title>
          <description>Subjects were orally administered FDC empa 10 mg/lina 5 mg and placebo matching to empa 10 mg for 24 wk during the double-blind treatment period.</description>
        </group>
        <group group_id="E4">
          <title>Plc (E10)</title>
          <description>Subjects were orally administered empa 10 mg and matching placebo to FDC empa 10 mg/lina 5 mg for 24 wk during the double-blind treatment period.</description>
        </group>
        <group group_id="E5">
          <title>Lina5 (E25)</title>
          <description>Subjects were orally administered FDC empa 25 mg/lina 5 mg and placebo matching to empa 25 mg for 24 wk during the double-blind treatment period.</description>
        </group>
        <group group_id="E6">
          <title>Plc (E25)</title>
          <description>Subjects were orally administered empa 25 mg and matching placebo to FDC empa 25 mg/lina 5 mg for 24 wk during the double-blind treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Calcinosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pharyngeal lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Dyshidrotic eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="352"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="354"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

